Impact of RNA- and Codon Optimization on Safety and Immunogenicity of HIV Candidate Vaccines
|
|
- Cory Roberts
- 6 years ago
- Views:
Transcription
1 Impact of RNA- and Codon Optimization on Safety and Immunogenicity of HIV Candidate Vaccines Ralf Wagner Molecular Microbiology and Gene Therapy Unit Institute of Medical Microbiology and Hygiene University of Regensburg
2 Integrated Vaccine Strategies Targets of immune response HIV Clades A (Africa) B (Europe, N & S-America) C (Asia,. ) E (Asia) F (Africa) G (South America, Africa) + + envelope proteins: Env structural proteins: Gag, Pol regulatory proteins: Tat, Rev, Nef accessory proteins: Vpr immunogen design molecular virology Immune response neutralizing AB mucosal immunity CD4+ T cell response CD8+ CTLs broad, cross clade, high quality, polyfunctional long term memory Delivery / Combination of Multivalent HIV/AIDS Vaccine Strategies Proteins Peptides DNA Viral Vectors Pseudovirions rad, NYVAC Novel Adjuvants (CpG, PEI, MF59) Bacterial Vectors? basic immunology / mice preclinic / rhesus macaques clinic / phase 1/2 (Bojak, Deml & Wagner, 22) Overview
3 Pr55 gag Necessary Component of HIV Vaccines Pr55 gag Intracellular targeting Gag-assembly Nc transport p17 MA p24 CA p7 p6 p6* PR RT Gag-assembly Capsid-reorganization Cyp A incorporation Capsid disassembly RNA-packaging Reverse transcription particle release vpr incorporation PR-activation (IC 5 13 µm) Pr16 gag-pol (Beissinger et al., 1996, Fitzon et al.,1999, Paulus et al.,1999, Paulus et al., 24; Ludwig et al., 27) Patients with strong Gag-Helper/CTL-Response control acute HIV infection better (Rosenberg et al., 1997; Ogg et al., 1999, many others) LTNP HIV infected individuals control HIV replication by T cells recognizing highly conserved epitopes within Gag (Harrer et al., 1998, Wagner et al., 1999, many others) Recombinant and chimeric Gag VLPs induce Th1 / CTL responses in Balb/C mice; Cross priming (Wagner et al., 1993, 1994, 1996; Bojak et al., 22, 23, 24, Deml et al.,1997a,b, 25) Gag VLP partially protective in Rhesus monkey model (Wagner et al., 1998; Notka et al., 1999a, b, Ludwig & Wagner, 27) Gag specific T-cells have been linked to better control of HIV replication Rationals for Immunogen Selection Molecular Virology
4 Late Lentiviral Gene Expression is Complex early RNAs late RNAs AAA RRE HIV-1 CRM1 NES Rev Ran GTP AAA Rev-dependent RNA export Inhibitory Sequences Splice Sites Cytoplasm cytoplasmat. RNAs ~9 kb ~4 kb ~2 kb late + Rev -early strong splice donor and weak splice acceptors capture RNAs within splicing machinery cis-located AU-rich repressor elements (INS) retain RNAs within the nucleus 1% 27% AAAAAA splicing machinery & INS binding proteins PABP? hnrnp C? AU-rich INS AAA Intrinsic risks: Ψ-sequence, recombination, RRE/Rev,... Bypassing Rev/RRE Regulation
5 Understanding Late Lentiviral Gene Expression early RNAs late RNAs AAA RRE HIV-1 Rev-dependent RNA export CRM1 NES Rev Ran GTP AAA Inhibitory Sequences Splice Sites Cytoplasm AA cytoplasmat. RNAs mammals HIV-1 late Ala GCC GCA Arg AGG AGA ~9 AsnkB AAC AAT Cys TGC TGT ~4 kb Gln CAG CAA Glu GAG GAA ~2 kb Gly GGC GGA + Rev -early Influence of various cis-acting sequences [INS, UTR (SD), RRE (SA)] wtgag UTR-wtgag wtgag-rre UTR-wtgag-RRE ΔSD1-wtgag-RRE syngag UTR-syngag syngag-rre UTR-syngag-RRE Bypassing Rev/RRE Regulation Thema
6 Facilitating Late Lentiviral Gene Expression syn-gag? cis active repressor degradation sequenzes wt - gag splicing machinery 3? ψ SD UTR RRE wt-gag constitutive nc export REV ran CRM1 REV RRE Northern Rev gag actin N syngag-rre UTR-wtgag-RRE UTR-wtgag-RRE C N C N C N C ΔSD1-wtgag-RRE RNA-and Codon Optimization
7 Consequencs of Modulated Late Lentiviral Gene Expression syn-gag? cis active repressor degradation sequenzes wt - gag splicing machinery 3? ψ SD UTR RRE wt-gag constitutive nc export REV ran CRM1 REV RRE HIV Vaccines facilitated gag-pol expression RNA nuclear export 5x no Rev, no RRE no 5 -UTR, no Ψ Risk for Recombination RNA Packaging Increased safety? Increased yields Enhanced Immunogenicity? Protein Production (CHO, PerC6) DNA Vaccines Bacterial DNA Delivery (Listeria) Adenoviral Vectors Herpesviral Vectors (EHV) Lentiviral Vectors Poxviral Vectors? Graf et al., 2; Wagner et al., 2; Deml et al., 21; Bojak et al., 23, Wild et al., 24, 27 RNA-and Codon Optimization
8 Impact of RNA & Codon Optimization in Poxviral Vectors wt - gag hu opt - gag hu opt cpg max -gag vaccinia - gag M NYVAC-Gag DNA-Gag WB - Antibody: CD-4/1 (anti p24 CA) NYVAC: No major impact of RNA & codon optimization on transgene expression DNA: Significant impact of RNA & codon optimization on transgene expression Conclusion: RNA- and codon-optimization recommended if various vector systems shall be compared / combined RNA-and Codon Optimization
9 Reduced Risk for Generating Replication Competent Recombinants...following RNA- and Codon-Optimization 2-Plasmid-system Transfervector gagpol - /Env + packaging construct wt vs syn cotransfection and harvest particles Permissive CD4+ cell culture system Replication post recombination Tat driven SEAP expression CMV BGHpA 1 E CMV U3 R U5 Ψ UTR * Ψ gag gag Δ pol pol Rev Recombination RCR vif rev1 vpr vpx RRE env tat1 tat2 Δ SFFV-Pr Δ Δ rev2 U3 R U5 * BGHpAd GFP SEAP non-replication competent HIV-reporter SEAP Aktivität wt syn syngp Sgp Δ 2 Mock days post transfection Safety Thema Profiles
10 Reduced Replicative Capacity of Engineered Recombinant HIVs chimeric viruses HIV-1 LTR gag codon-modified sequence pol Cla I Nsp V Spe I Apa I Bcl I frameshift en v wild-type sequence LTR Mutant: Codon-optimized region (gag ATG=112): HXCS 5 gag (bp ) HXNS 5 gag (bp ) HXSA 3 gag (bp ) HX Hxsyn gag/pol (bp ) Processing & maturation cells viral particles HXCS HXNS HXSA HX1 HXsyn Gag p24 Gag p24 env RNA splicing & export n c HXCS HXNS HXSA HX1 HXsyn 12 h p.t. 9 kb 4 kb 2 kb 9 kb 4 kb 2 kb (Wagner et al., 2; Steck et al., in prep.) Viral infectivity p24 [ng/ml] Replication kinetics (MT4) HXSA HX days Safety Thema Profiles
11 RNA and Codon Optimization DNA Vaccines Increased immunogenicity in BALB/c mice isotype titers IgG1 IgG2a pg pg im im wt-gag syngag wt-gag syngag cytokine secretion (pg/ml) pg IL-5 IFN-γ pg im im wt-gag syngag wt-gag syngag NET specific lysis (%) wt- gag (p.g.) syngag (p.g.) wt- gag (i.m.) syngag (i.m.) mock Wt-Gag: No Gag specific antibodies, IFN-g or CTLs detected Syn Gag: High levels of gag specific antibodies and IFN-g; CTL induction 1 Im (Th1, CTL) >>> pg (Th2) E/T Immunogenicity Thema
12 Molecular Epidemiology: Prerequisite for Immunogen Design India China C B Asia C C B B C B C C B B Prevalence Incidence Virus population Regional clustering Host genetic background Subcloning pcr-script Sequence analysis of C (CN54) tev vif tat rev LTR LTR pol vpr gag env vpu Graf et al., 1998, Su et al., 2 Clade Delivery Status Developer / Manufacturer GagPolNef C (CN54) DNA-C GMP, B, T, I, Fill. Wagner / Wolf / Cobra Env C (CN54) DNA-C GMP, B, T, I, Fill. Wagner / Wolf / Cobra GagPolNef / Env C (CN54) NYVAC-C GMP, B, T, I, Fill. Sanofi Pasteur GagPolNef / Env C (CN54) MVA-C GMP in progress Esteban GagPolNef / Env C (CN54) vtt-c in progress Y. Shao / S-CDC GagPolNef / Env B NYVAC-B GMP, B, T, I, Fill. Sanofi Pasteur GagPolNef / Env B MVA-B GMP, B, T, I, Fill. Esteban cgmp Immunogens Thema
13 In vivo Studies in Rhesus Monkeys Mimicking a Human Phase I Trial CMI CMI CMI CMI CMI CMI NYVAC/C i.m. NYVAC/C i.m. CMI CMI CMI CMI CMI CMI CMI CMI CMI monkeys per group DNA/C DNA/C NYVAC/C i.m. NYVAC/C i.m. Preclinical Trials
14 In vivo Studies in Rhesus Monkeys Mimicking a Human Phase I Trial Antigen-specific IFNγ release at week 24 (4 weeks after 1st NYVAC) number of peptide pools Rl187 Rl432 Rl / NYVAC-C DNA-C / NYVAC-C C54 Rl313 Rl457 C24 Rl346 Rl1147 C28 2/1 respond 8/1 respond several pools recognised Rl468 Rl543 C136 Rl45 Rl474 Rl12165 C145 Rl467 Rl58 C86 gag1 gag2 pol1 pol2 pol3 env1 env2 Preclinical Trials P. Mooij, J. Heeney et al.
15 In vivo Studies in Rhesus Monkeys / NYVAC-C DNA-C / NYVAC-C Ri346 C24 Ri Ri12165 C145 Ri58 Ri474 Ri45 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 number of responders week IFNγ IL-2 IL-4 C28 Ri1147 Ri346 C24 Ri12133 Ri IFNγ IL-2 IL-4 Ri12165 C145 Ri58 Ri474 Ri45 Ri543 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 gag 1 gag 2 pol 1 pol 2 pol 3 env 1 env 2 number of responders week 26 IFNγ IL-2 IL-4 IFNγ IL-2 IL-4 Preclinical Trials P. Mooij, J. Heeney et al.
16 EV2: Study Design HIV Negative Volunteers Objective: Determine the impact of DNA-C versus NYVAC-C alone on priming T-cell responses Study design: 2 x 2 HIV negative volunteers A. DNA-C prime (W, W4; 4mg im), NYVAC-C boost (W2, W24; 2x1E7 im) B. NYVAC-C (W2, W24; 2x1E7 im) London (MRC; J.Weber, S. McCormack), Lausanne (CHUV; G. Pantaleo) Readout (Lausanne): Several time points ELISPOT analysis (γifn, IL2) FACS analysis (CD4, CD8, CCR7, IL2, γifn) T cell phenotype / function Epitope mapping Phase I Clinical Trial
17 EV2: Percentage of Responders (γifn+ T cells) A Percentage of responder NYVAC C Alone (n=15) P =.3 DNA C + NYVAC C (n=2) B Percentage of responders P <.1 P =.1 P <.1 P =.19 NYVAC C alone DNA C + NYVAC C W W5 W2 W24 W26 W28 W48 DNA-C NYVAC-C Higher percentage of responders in DNA-C prime / NYVAC-C boost group (>9%) compared to NYVAC-C group (<4%) Durability DNA-C / NYVAC-C >> NYVAC-C Phase I Clinical Trial A. Harrari, G.Pantaleo et al.
18 EV2: Magnitude of T cell Responses (γifn) A DNA C + NYVAC C SFU / 1 6 cells ES1 W W5 W2 W24 W26 W28 W ES2 W W5 W2 W24 W26 W28 W ES8 W W5 W2 W24 W26 W28 W ES1 W W5 W2 W24 W26 W28 W ES11 W W5 W2 W24 W26 W28 W48 SFU / 1 6 cells ES23 W W5 W2 W24 W26 W28 W W ES24 W5 W2 W24 W26 W28 W ES26 W W5 W2 W24 W26 W28 W EU3 W W5 W2 W24 W26 W28 W EU5 W W5 W2 W24 W26 W28 W48 SFU / 1 6 cells EU9 W W5 W2 W24 W26 W28 W EU11 W W5 W2 W24 W26 W28 W EU12 W W5 W2 W24 W26 W28 W48 DNA C (W and W4) NYVAC C (W2 and W24) Neg GAG 1 GAG 2 GAG/POL POL1 POL2 NEF ENV NYVAC C Alone SFU / 1 6 cells ES3 W W5 W2 W24 W26 W28 W ES4 W W5 W2 W24 W26 W28 W ES6 W W5 W2 W24 W26 W28 W ES2 W W5 W2 W24 W26 W28 W EU7 W W5 W2 W24 W26 W28 W48 Phase I Clinical Trial A. Harrari, G.Pantaleo et al.
19 EV2: Magnitude of T cell Responses (γifn) B Env Responses C Gag/Pol/Nef Responses 1 DNA C + NYVAC C 1 NYVAC C alone 4 SFU/1 6 cells SFU/1 6 cells Week Week Week 26 Week 28 Week 26 Week 28 DNA C + NYVAC C NYVAC C alone D Percentage NYVAC C DNA C + NYVAC C Higher magnitude of T cell reponses in DNA-C prime / NYVAC-C boost group (>9%) compared to NYVAC-C group (<4%) Env >> GagPolNef SFU/1 6 cells Phase I Clinical Trial A. Harrari, G.Pantaleo et al.
20 EV2: Functional Analysis of T cell Responses A Volunteer # EU11, DNA C + NYVAC C Gated on CD4 T cells IL-2 % % % TNF-α.2% % % CD4.34% Neg CD4 and CD8 responses are polyfunctional.4%.7%.11%.9 6.6% Env (IL-2, γifn, TNFα) IFN-γ.3% IFN-γ.1% CFSE B Volunteer # EU11, DNA C + NYVAC C Gated on CD8 T cells %.1% % 1.1% %.1% IL-2 % TNF-α % CD17a % CD8 Neg.7%.3% %.8% 1.94% Env.22.3%.17 IFN-γ IFN-γ IFN-γ CFSE Phase I Clinical Trial A. Harrari, G.Pantaleo et al.
21 EV2: Epitope specific T cell Responses A 8 number of epitopes C Gated on CD8 T cells #ES26 #ES2 Number of ENV epitopes ES2 ES8 ES16 ES2 ES21 ES23 ES26 EU3 EU11 IL Unstimulated LTKKNYSENSSEYYR ----NYSENSSEY-- B Gated on CD4 T cells #ES26 #ES23 NEG NEG YSENSSEYY SENSSEYYR.1.1 IFN-γ IL FYRLDIVPLTKKNYS ENVTENFNMWKNEMV IFN-γ D pentamer #EU16 HLA-A*11-YSENSSEYY.9 CD8 T cell responses are broad (mean 4,2 epitopes) and polyfunctional Phase I Clinical Trial A. Harrari, G.Pantaleo et al.
22 EV2: Longevity of T cell Responses (γifn, IL2) A NYVAC C Alone DNA C + NYVAC C SFU / 1 6 cells # ES4 * * * W28 W48 W # ES2 # ES8 #ES * * 45 * * * W28 W48 W72 W28 W48 W72 W28 W48 W72 6 * * * Neg GAG 1 GAG 2 GAG/POL POL1 POL2 NEF ENV B Responses are durable SFU / 1 6 cells (mean±se) DNA C + NYVAC C NYVAC C alone W28 W48 W72 7% positivity at W72 (DNA-C / NYVAC-C) ~3 SFU / 1E6 cells at W72 Phase I Clinical Trial A. Harrari, G.Pantaleo et al.
23 Dominant Env- / Mitigated Gag Responses Possible explanations: Intracellular trafficking / localisation: gp12 secreted, GagPolNef not Gp12: 55 kda + glycosylation; GPN: 16 kda non glycosylated Gag expression >>> GagPolNef; SIV-Gag >> HIV-Gag Env vs GagPolNef: competition for HLA epitope presentation Modifications: Altered immunization regimen: 3 x DNA-C (mixture DNA-GPN and DNA- Env) followed by 1 x NYVAC-C (EV3) instead 2 x DNA-C followed 2 x NYVAC-C (EV2) At least 2 different NYVAC viruses: Env + GagPolNef instead Env / GagPolNef; different inoculation sites Increase immunogen processing and epitope presentation DRIP Improve cross-presentation: VLP / secreted Gag derivatives Targeting to DCs (e.g. Dec25 targeting, FcR targeting) Incorporate molecular adjuvants (CD4L, CTB...) Immunogen Design
24 Outlook: BMGF-PTVDC Discovery Group Myr- (A) ΔFS Pr - (D N) scnef Gag Pr RT-N C N RT-C RT Myr- (A) Myr+ (A G) Myr- (A) Myr+ (A G) Myr+ (A G) Signal peptide Gag Gag +FS Gag Pr - (D N) ΔNef Gag Gag Gag +FS +FS +FS +FS Pr - (D N) scnef Pr RT-N C N RT-C RT Pr - (D N) scnef Pr RT-N C N RT-C RT Pr RT-N RT-C RT Pr - (D N) ΔNef Pr RT-N RT-C RT Pr - (D N) Pr RT-N RT-C RT scdec25-ab Gag reference construct allow ribosomal frameshifting (Gag 95 / PolNef 5) allow ribosomal frameshifting (Gag 95 / PolNef 5), VLP budding allow ribosomal frameshifting No NEF, (Gag 95 / Pol 5) allow ribosomal frameshifting No NEF, VLP budding 2 distinct ORFs secretion, DC targeting best in class: increase expression & improve access to DRIP pathway Immunogen design
25 What we have achieved Where we need to go Targets of immune response HIV Clades A (Africa) B (Europe, N & S-America) C (Asia, Africa ) E (Asia) F (Africa) G (South America, Africa) + + envelope proteins: Env structural proteins: Gag, Pol regulatory proteins: Tat, Rev, Nef accessory proteins: Vpr immunogen design molecular virology Immune response neutralizing AB mucosal immunity CD4+ T cell response CD8+ CTLs broad, cross clade, high quality, polyfunctional long term memory Delivery / Combination of Multivalent HIV/AIDS Vaccine Strategies Proteins Peptides DNA Viral Vectors Novel Adjuvants (CpG, PEI, MF59)? basic immunology / mice preclinic / rhesus macaques clinic / phase 1/2 Pseudovirions Ad, NYVAC Bacterial Vectors Summary
26 Acknowledgements Universität Regensburg RIMMH, Hans Wolf Christine Ludwig Benedikt Asbach Asli Bauer Andi Alex Kliche Thomas Benen Ruth Kapzan Tim Henrik Bruun Kristina Schilling Jens Wild Veronika Wanninger Denijal Kosovac Helga Hofmann Josef Köstler Yvonne Ködel Katharina Böckl Simon Bredl Nikole Kirner Supported by: EC 6th Framework CHIVAC, EUROVAC, DECVAC (GENEART) BMGF PTVDC, VDAC NIH HIVRAD BMBF HIVCOMPMET Bavarian Res. Foundation Hektor Foundation BPRC (NL) Jonathan Heeney Petra Mooij Sunita Balla Sanofi Pasteur Jim Tartaglia Marie-Joelle Frachette CAPM (China) Shao Yiming, Ling Su CHUV, CH Guiseppe Pantaleo Alexandre Harrari Pierre A. Bart MRC, UK Jonathan Weber Sheena McCormac Thema
Trial Objectives immunogenicity safety
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injections. Long term Results of the EV03/ANRS Vac20 Phase I/II Trial. Yves Levy, Kim Ellefsen, Wolfgang Stöehr, Pierre-Alexandre
More informationAn HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
ARTICLE An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses The Journal of Experimental Medicine CORRESPONDENCE Giuseppe Pantaleo:
More informationAltering an Artificial Gagpolnef Polyprotein and Mode of ENV Co-Administration Affects the Immunogenicity of a Clade C HIV DNA Vaccine
Altering an Artificial Gagpolnef Polyprotein and Mode of ENV Co-Administration Affects the Immunogenicity of a Clade C HIV DNA Vaccine Katharina Böckl 1., Jens Wild 1., Simon Bredl 1 a, Kathrin Kindsmüller
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationVIROLOGY. Engineering Viral Genomes: Retrovirus Vectors
VIROLOGY Engineering Viral Genomes: Retrovirus Vectors Viral vectors Retrovirus replicative cycle Most mammalian retroviruses use trna PRO, trna Lys3, trna Lys1,2 The partially unfolded trna is annealed
More informationViral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP
Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP 1 Learning Objectives Recognize hazards associated with viral vectors in research and animal
More informationRetroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase.
Retroviruses ---The name retrovirus comes from the enzyme, reverse transcriptase. ---Reverse transcriptase (RT) converts the RNA genome present in the virus particle into DNA. ---RT discovered in 1970.
More informationSupplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins
Supplementary information inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins Takuya Tada, Yanzhao Zhang, Takayoshi Koyama, Minoru Tobiume, Yasuko Tsunetsugu-Yokota, Shoji
More informationHIV/AIDS: Molecular Biology and pathogenesis. George N. Pavlakis National Cancer Institute, USA
HIV/AIDS: Molecular Biology and pathogenesis George N. Pavlakis National Cancer Institute, USA Infection RNA Export, packaging Virion formation RNA Reverse transcription DNA RNA Integration Transcription
More informationFostering Clinical Development for HIV-1 Vaccine
W Fostering Clinical Development for HIV-1 Vaccine Ravimiarenduse alane seminar 9. oktoobril Tallinnas Mart Ustav, PhD CSO, SVP 1 FIT Biotech Founded in 1995 Operations in Tampere, Finland and Tartu, Estonia
More informationNew Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More informationProfessor Jonathan Weber
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationAn AIDS vaccine: Why is it so difficult?
An AIDS vaccine: Why is it so difficult? Jaap Goudsmit, MD, PhD Professor of Poverty-related Communicable Diseases, AMC Chairman of the Board CPCD CSO, Crucell Holland BV An AIDS vaccine: Why is it so
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationEngineering an in vitro human immune system for rapid vaccine evaluation
Engineering an in vitro human immune system for rapid vaccine evaluation William Warren, Ph.D. VaxDesign Corporation Orlando, FL 32826 wwarren@vaxdesign.com www.vaxdesign.com 1 MIMIC Technology Overview
More informationL I F E S C I E N C E S
1a L I F E S C I E N C E S 5 -UUA AUA UUC GAA AGC UGC AUC GAA AAC UGU GAA UCA-3 5 -TTA ATA TTC GAA AGC TGC ATC GAA AAC TGT GAA TCA-3 3 -AAT TAT AAG CTT TCG ACG TAG CTT TTG ACA CTT AGT-5 OCTOBER 31, 2006
More informationUnder the Radar Screen: How Bugs Trick Our Immune Defenses
Under the Radar Screen: How Bugs Trick Our Immune Defenses Session 7: Cytokines Marie-Eve Paquet and Gijsbert Grotenbreg Whitehead Institute for Biomedical Research HHV-8 Discovered in the 1980 s at the
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationDevelopment of a Universal T Cell Vaccine. Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom
Development of a Universal T Cell Vaccine Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom Development of HIV-1 vaccines Induction of cell-mediated responses Immunogens
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationStreamlining Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in
JVI Accepted Manuscript Posted Online 10 February 2016 J. Virol. doi:10.1128/jvi.03135-15 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Streamlining Heterologous DNA-Prime
More informationFeb 11, Gene Therapy. Sam K.P. Kung Immunology Rm 417 Apotex Center
Gene Therapy Sam K.P. Kung Immunology Rm 417 Apotex Center Objectives: The concept of gene therapy, and an introduction of some of the currently used gene therapy vector Undesirable immune responses to
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 RETROVIRUSES. 2. HTLV-II causes hairy T-cell leukemia
1 of 7 I. Diseases Caused by Retroviruses RETROVIRUSES A. Human retroviruses that cause cancers 1. HTLV-I causes adult T-cell leukemia and tropical spastic paraparesis 2. HTLV-II causes hairy T-cell leukemia
More informationEmploying Improved Antigens Allows Streamlining of Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in Rhesus Macaques
Title Employing Improved Antigens Allows Streamlining of Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in Rhesus Macaques Running title: Improved HIV Antigens and Delivery Schedules
More informationSequence Analysis of Human Immunodeficiency Virus Type 1
Sequence Analysis of Human Immunodeficiency Virus Type 1 Stephanie Lucas 1,2 Mentor: Panayiotis V. Benos 1,3 With help from: David L. Corcoran 4 1 Bioengineering and Bioinformatics Summer Institute, Department
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationRecombinant adeno-associated virus vectors induce functionally impaired transgene product specific CD8 + T cells in mice
Recombinant adeno-associated virus vectors induce functionally impaired transgene product specific CD8 + T cells in mice Shih-Wen Lin,, Marcio O. Lasaro, Hildegund C.J. Ertl J Clin Invest. 2007;117(12):3958-3970.
More informationHIV acute infections and elite controllers- what can we learn?
HIV acute infections and elite controllers- what can we learn? Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) and HIV Pathogenesis Programme (HPP), Doris Duke
More informationProkaryotic Biology. VIRAL STDs, HIV-1 AND AIDS
Prokaryotic Biology VIRAL STDs, HIV-1 AND AIDS Prokaryotic Biology FROM THE CDC VIRAL STDs, HIV-1 AND AIDS VIRAL STDs & CONTACT VIRAL DISEASES A. GENITAL HERPES & COLD SORES 1. HERPES SIMPLEX VIRUS-2 (HHV-2)
More informationReplicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.
Replicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.6P Frédéric Tangy Viral Genomics and Vaccination Laboratory Measles
More informationSupplemental Figure 1
Supplemental Figure 1 1a 1c PD-1 MFI fold change 6 5 4 3 2 1 IL-1α IL-2 IL-4 IL-6 IL-1 IL-12 IL-13 IL-15 IL-17 IL-18 IL-21 IL-23 IFN-α Mut Human PD-1 promoter SBE-D 5 -GTCTG- -1.2kb SBE-P -CAGAC- -1.kb
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationHigher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
More informationAIDSVaccine2010 Atlanta, Georgia Willy Bogers. NIH HIVRad Grant nr 5P01AI066287
HIV-1 envelope-cd4 receptor complexes elicit broad T- and B- cell immune responses as well as cross-reactive neutralizing antibodies in Rhesus macaques NIH HIVRad Grant nr 5P01AI066287 AIDSVaccine2010
More informationCationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants
Cationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants September 29, 28 Platform Technology Proprietary Cationic Lipid-DNA Complexes Cationic/Neutral Lipid + DNA = JVRS-1 JVRS-1 + Antigen
More informationGp96-Ig-SIV VACCINES INDUCE PREDOMINANT IMMUNE RESPONSES AT MUCOSAL SITES
Gp96-Ig-SIV VACCINES INDUCE PREDOMINANT IMMUNE RESPONSES AT MUCOSAL SITES Natasa Strbo M.D. Ph.D. Paris, AIDS Vaccine 29 October 19 22 Why is cell secreted gp96 Ig vaccine approach innovative and unconventional?
More informationRecombinant adeno-associated virus vectors induce functionally impaired transgene product specific CD8 + T cells in mice
Research article Recombinant adeno-associated virus vectors induce functionally impaired transgene product specific CD8 + T cells in mice Shih-Wen Lin, 1,2 Scott E. Hensley, 1,2 Nia Tatsis, 2 Marcio O.
More informationCharacterizing intra-host influenza virus populations to predict emergence
Characterizing intra-host influenza virus populations to predict emergence June 12, 2012 Forum on Microbial Threats Washington, DC Elodie Ghedin Center for Vaccine Research Dept. Computational & Systems
More informationSupplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR
Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4
More informationSupporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
More informationHIV Immunopathogenesis. Modeling the Immune System May 2, 2007
HIV Immunopathogenesis Modeling the Immune System May 2, 2007 Question 1 : Explain how HIV infects the host Zafer Iscan Yuanjian Wang Zufferey Abhishek Garg How does HIV infect the host? HIV infection
More informationc Tuj1(-) apoptotic live 1 DIV 2 DIV 1 DIV 2 DIV Tuj1(+) Tuj1/GFP/DAPI Tuj1 DAPI GFP
Supplementary Figure 1 Establishment of the gain- and loss-of-function experiments and cell survival assays. a Relative expression of mature mir-484 30 20 10 0 **** **** NCP mir- 484P NCP mir- 484P b Relative
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationHIV INFECTION: An Overview
HIV INFECTION: An Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationDevelopment of Broadly Reactive HIV-1/AIDS Virus-like Particle Vaccines. Sean Patrick McBurney. B.S. Microbiology, University of Pittsburgh, 2004
Development of Broadly Reactive HIV-1/AIDS Virus-like Particle Vaccines by Sean Patrick McBurney B.S. Microbiology, University of Pittsburgh, 2004 Submitted to the Graduate Faculty of School of Medicine
More informationDNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
More informationHIV and drug resistance Simon Collins UK-CAB 1 May 2009
HIV and drug resistance Simon Collins UK-CAB 1 May 2009 slides: thanks to Prof Clive Loveday, Intl. Clinical Virology Centre www.icvc.org.uk Tip of the iceberg = HIV result, CD4, VL Introduction: resistance
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationCURRENT DEVELOMENTS AND FUTURE PROSPECTS FOR HIV GENE THERAPY USING INTERFERING RNA-BASED STRATEGIES
[Frontiers in Bioscience 5, d527-555, May 1, 2000] CURRENT DEVELOMENTS AND FUTURE PROSPECTS FOR HIV GENE THERAPY USING INTERFERING RNA-BASED STRATEGIES Betty Lamothe, Sadhna Joshi Department of Medical
More informationThe humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
More informationMina John Institute for Immunology and Infectious Diseases Royal Perth Hospital & Murdoch University Perth, Australia
Mina John Institute for Immunology and Infectious Diseases Royal Perth Hospital & Murdoch University Perth, Australia AIDSvaccine conference, 14 th September 2011 IMGT HLA database July 2011 >5000 class
More informationDevelopment of a VP6 subunit rotavirus vaccine A dual role of VP6 as a vaccine antigen and an adjuvant
30 August 2018, Minsk 13TH INTERNATIONAL ROTAVIRUS SYMPOSIUM Development of a VP6 subunit rotavirus vaccine A dual role of VP6 as a vaccine antigen and an adjuvant Dr. Vesna Blazevic Head of Laboratory
More informationProgress on new vaccine strategies against chronic viral infections
Progress on new vaccine strategies against chronic viral infections Jay A. Berzofsky,, Masaki Terabe, Igor M. Belyakov J Clin Invest. 2004;114(4):450-462. https://doi.org/10.1172/jci22674. Review Among
More informationHIV & AIDS: Overview
HIV & AIDS: Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR VJ TEMPLE 1 What
More informationSystem Biology analysis of innate and adaptive immune responses during HIV infection
System Biology analysis of innate and adaptive immune responses during HIV infection Model of T cell memory persistence and exhaustion Naive Ag+APC Effector TEM (Pfp, Gr.B, FasL, TNF) Ag stim. IL-2, IL-7,
More informationSection 6. Junaid Malek, M.D.
Section 6 Junaid Malek, M.D. The Golgi and gp160 gp160 transported from ER to the Golgi in coated vesicles These coated vesicles fuse to the cis portion of the Golgi and deposit their cargo in the cisternae
More informationEV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-nyvac-c boost to NYVAC-C alone
Vaccine (2008) 26, 3162 3174 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/vaccine EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-nyvac-c
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Adaptive Immunity Innate immunity: (Antigen - nonspecific) defense
More informationCD4 + T-cell-inducing HIV vaccines may have an impact on viral control
CD4 + T-cell-inducing HIV vaccines may have an impact on viral control Clues from cytokines produced by CD4 + T-cells from HIVinfected patients and vaccinated seronegative volunteers Eva Van Braeckel 1,
More informationApplication of Reverse Genetics to Influenza Vaccine Development
NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective
More informationImmunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239
Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239 Bin Jia 1, Sharon K. Ng 1, M. Quinn DeGottardi 1, Michael Piatak Jr. 2, Eloísa Yuste
More informationOctober 26, Lecture Readings. Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell
October 26, 2006 Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell 1. Secretory pathway a. Formation of coated vesicles b. SNAREs and vesicle targeting 2. Membrane fusion a. SNAREs
More information~Lentivirus production~
~Lentivirus production~ May 30, 2008 RNAi core R&D group member Lentivirus Production Session Lentivirus!!! Is it health threatening to lab technician? What s so good about this RNAi library? How to produce
More informationTherapeutic vaccines for HCV Chasing a Moving Target
Therapeutic vaccines for HCV Chasing a Moving Target Ellie Barnes (Fondation Merieux-Annecy March 213) Do we need a vaccine for HCV? HCV infects 17 million people worldwide Leading cause of end-stage
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationA Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire.
Company LOGO A Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire. Fayaz Ahmad Mir, Stefan H. E. Kaufmann,
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationPD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8 + T cells in mice
Research article PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8 + T cells in mice Jingying Zhou, 1 Allen K.L. Cheung, 1 Zhiwu Tan, 1 Haibo Wang, 1 Wenbo Yu, 1 Yanhua Du, 1 Yuanxi Kang, 1 Xiaofan
More informationNIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2009 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Nature. 2009 January 1; 457(7225): 87 91. doi:10.1038/nature07469. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in
More informationHeterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection
Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection Enterprise Meeting: The Appropriate Use of Tiered Virus Panels when Assessing HIV-1 Vaccine-elicited Neutralizing Antibodies" July 7 th,
More informationHIV-1 Vaccine Development: Recent Advances in the CTL Platform Spotty Business ACCEPTED
JVI Accepts, published online ahead of print on 7 November 2007 J. Virol. doi:10.1128/jvi.01634-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationHIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
More informationNovel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants
Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017 Office of AIDS Research OAR Responsibilities
More informationHIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
More informationHIV-1 SUBTYPE C MOTHER-TO-CHILD TRANSMISSION: GENETIC AND IMMUNOLOGIC CORRELATES. Elizabeth Susan Russell
HIV-1 SUBTYPE C MOTHER-TO-CHILD TRANSMISSION: GENETIC AND IMMUNOLOGIC CORRELATES Elizabeth Susan Russell A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial
More informationPart One Immunology and Vaccination Strategies for AIDS and TB
Part One Immunology and Vaccination Strategies for AIDS and TB AIDS and Tuberculosis: A Deadly Liaison. Edited by Stefan H.E. Kaufmann and Bruce D. Walker Copyright Ó 2009 WILEY-VCH Verlag GmbH & Co. KGaA,
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationChoosing Between Lentivirus and Adeno-associated Virus For DNA Delivery
Choosing Between Lentivirus and Adeno-associated Virus For DNA Delivery Presenter: April 12, 2017 Ed Davis, Ph.D. Senior Application Scientist GeneCopoeia, Inc. Outline Introduction to GeneCopoeia Lentiviral
More informationHepatitis virus immunity. Mar 9, 2005 Rehermann and Nascimbeni review Crispe review
Hepatitis virus immunity Mar 9, 2005 Rehermann and Nascimbeni review Crispe review HBV & HCV infection outcomes Both viruses cause immune-mediated active and chronic hepatitis HBV Vertical transmission
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus 1. Identification of the AIDS Virus a) opportunistic infections observed in homosexual men (all had T4 helper cell depletion) -> termed Acquired Immune Deficiency Syndrome;
More informationGenerating kisspeptin cell lines to investigate their role in reproduction
Generating kisspeptin cell lines to investigate their role in reproduction Dakota C. Jacobs 1 Jadwiga M. Giebultowicz 2, and Patrick E. Chappell 3 1 Bioresource Research, 2 Department of Integrative Biology,
More informationCombining Pharmacology and Mutational Dynamics to Understand and Combat Drug Resistance in HIV
Combining Pharmacology and Mutational Dynamics to Understand and Combat Drug Resistance in HIV A dissertation submitted for the degree of Doctor of Philosophy by Max von Kleist, B.Sc., M.Sc. Supervisor:
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More information5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1
Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.
More informationSupplemental Data. Shin et al. Plant Cell. (2012) /tpc YFP N
MYC YFP N PIF5 YFP C N-TIC TIC Supplemental Data. Shin et al. Plant Cell. ()..5/tpc..95 Supplemental Figure. TIC interacts with MYC in the nucleus. Bimolecular fluorescence complementation assay using
More informationDNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2004, p. 370 389 Vol. 17, No. 2 0893-8512/04/$08.00 0 DOI: 10.1128/CMR.17.2.370 389.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. DNA
More informationLentiviruses: HIV-1 Pathogenesis
Lentiviruses: HIV-1 Pathogenesis Human Immunodeficiency Virus, HIV, computer graphic by Russell Kightley Tsafi Pe ery, Ph.D. Departments of Medicine and Biochemistry & Molecular Biology NJMS, UMDNJ. e-mail:
More informationImmunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239
University of Massachusetts Medical School escholarship@umms Preventive and Behavioral Medicine Publications and Presentations Preventive and Behavioral Medicine 1-23-2009 Immunization with single-cycle
More informationCertificate of Analysis
Certificate of Analysis Catalog No. Amount Lot Number 631987 10 μg Specified on product label. Product Information plvx-ef1α-ires-mcherry is a bicistronic lentiviral expression vector that can be used
More information, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic
1 Two attributes make AIDS unique among infectious diseases: it is uniformly fatal, and most of its devastating symptoms are not due to the causative agent Male to Male sex is the highest risk group in
More informationIdentification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing
More informationRunning Head: AN UNDERSTANDING OF HIV- 1, SYMPTOMS, AND TREATMENTS. An Understanding of HIV- 1, Symptoms, and Treatments.
Running Head: AN UNDERSTANDING OF HIV- 1, SYMPTOMS, AND TREATMENTS An Understanding of HIV- 1, Symptoms, and Treatments Benjamin Mills Abstract HIV- 1 is a virus that has had major impacts worldwide. Numerous
More informationFig. 1: Schematic diagram of basic structure of HIV
UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR HIV & AIDS: An Overview What is HIV?
More informationI m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.
Supplementary Material Appendix 1 Here we show that independent inhibition by a single drug of two distinct steps (A and ) in the viral life cycle results in a non-linear median effect dose-response curve
More information